NRx Pharmaceuticals announced it received written notice on December 1 from The Nasdaq Stock Market informing NRx Pharmaceuticals that it has regained compliance with the minimum bid price requirement under the Nasdaq Listing Rule 5450 and the matter is now closed. Nasdaq staff made this determination after NRx Pharmaceuticals’ closing bid price was above $1.00 per share for 10 consecutive business days from November 16 to November 30.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on NRXP:
